Adjust text size: A | A | A

Lung Cancer Research Programs

2008

  • Poulikos I. Poulikakos Ph.D.

    An important feature in most cases of non-small cell lung cancer (NSCLC) is the deregulation of the classical MAPK (mitogen-activated protein kinase) pathway. The MAPK pathway consists of enzymes...

    | More…

  • Rajagopal Ramesh Ph.D.

    Progress in understanding the molecular cause of lung cancer has resulted in the identification of the epidermal growth factor receptor (EGFR) as an important player in lung tumor cell creation,...

    | More…

  • Lynne Regan Ph.D.

    All cancers result from the aberrant growth of previously normal cells. As the understanding of the molecular basis of cancer develops, scientists are able to identify the specific proteins whose...

    | More…

  • E. Aubrey Thompson Ph.D.

    Mutations of the epidermal growth factor receptor (EGFR) gene are relatively uncommon among non-small cell lung cancer (NSCLC) patients. However, such mutations are observed with high frequency in...

    | More…

  • Rolf A. Brekken Ph.D.

    Anti-angiogenic therapies are a rapidly growing group of drugs used for the treatment of cancer. This category of drugs works by targeting the blood vessels, or vasculature, in a tumor in an...

    | More…

2007

  • Mark M. Fuster M.D.

    Lung cancer is the leading cause of cancer death in the United States and worldwide. Research on the biology of one subtype known as bronchioalveolar carcinoma (BAC) has been limited and...

    | More…

  • Yixuan Gong M.D.

    Lung cancer is the leading cause of cancer-related death in the US and worldwide. For patients with metastatic non-small cell lung cancer (NSCLC), median survival is 10-12 months with...

    | More…

  • D. Neil Hayes M.D., MPH

    Cancers of the lung and bronchus claim over 160,000 lives per year in the United States alone, which is greater than the combined deaths from colon, breast, and prostate cancer. The major...

    | More…

  • John Heymach M.D., Ph.D.

    Emerging evidence indicates that there are gender-specific differences in the biology of lung cancer and in the therapeutic response to new molecularly-targeted agents. Women, particularly non-...

    | More…

  • Federico Innocenti Ph.D.

    The treatment of patients with bronchioalveolar carcinoma (BAC) is far from optimal and new strategies to improve the survival of these patients are needed. One way to increase the chance of...

    | More…

Spread the word

Share |

Sign up for Updates from Uniting

Uniting Against Lung Cancer: 27 Union Square West, Suite 304, New York, NY 10003 • Tel: 212.627.5500 • Fax: 212.627.7594. Privacy Policy
Uniting Against Lung Cancer is a tax exempt 501(c)(3) nonprofit corporation with the EIN 13 419 5464.

Site design & development by Raised Eyebrow Web Studio, Inc.